Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Key Points

• The research aims to assess the effectiveness and tolerability of weekly RVD regimens in transplant-ineligible patients with newly diagnosed myeloma.
• Multicenter study conducted in Australia
• Participants received weekly bortezomib, lenalidomide, and dexamethasone (RVD)
• Outcomes measured included efficacy and toxicity
• Weekly RVD regimens showed comparable efficacy to twice-weekly regimens
• Toxicity levels remained a significant concern for patients